Blog Archive
-
▼
2007
(88)
-
▼
November
(11)
- Regenetech , Preclinical Studies at Johns Hopkins ...
- Cardium, Phase 2b Excellarate Clinical Study for D...
- DexCom, FDA Approval to Calibrate Its SEVEN Contin...
- DIAMYD, A TYPE 1 DIABETES TRIAL WITH THE EXPERIMEN...
- JDRF and Lilly, Research to Identify Beta Cell Bio...
- Osiris Therapeutics, Phase II Clinical Trial Evalu...
- CV Therapeutics' Anti-Ischemic Agent Ranexa(R), Re...
- Sangamo BioSciences, ZFP Therapeutic Data From Ner...
- Sirtris, Novel Endogenous SIRT1 Activator
- Forbes Medi-Tech, Final Steps in Compound Selecti...
- Nanomix, Exclusive Glucose Detection Licensing Agr...
-
▼
November
(11)
Friday, November 23, 2007
JDRF and Lilly, Research to Identify Beta Cell Biomarkers
Nov 14, 2007 - The Juvenile Diabetes Research Foundation and Eli Lilly and Company announced today that they are joining together to create a $3 million research effort to accelerate the pace of research into drugs and therapies to cure diabetes and its complications by developing biomarkers -- indicators that can measure the progress of disease and the effectiveness of therapeutics... Lilly's Press Release -